Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

NCT04847466 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

NIH

Sponsor class

Conditions

Gastroesophageal Junction (GEJ) Cancers
Advanced HNSCC

Interventions

DRUG: N-803
DRUG: Pembrolizumab
BIOLOGICAL: PD-L1 t-haNK

Sponsor

National Cancer Institute (NCI)